-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

Benzinga·10/26/2026 11:56:14
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.